New Risk • Apr 21
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.1% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Paying a dividend despite having no free cash flows. Minor Risks Profit margins are more than 30% lower than last year (4.1% net profit margin). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€57.0m market cap, or US$67.0m). New Risk • Apr 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€56.7m market cap, or US$66.9m). Announcement • Apr 14
Magis S.p.A., Annual General Meeting, Apr 28, 2026 Magis S.p.A., Annual General Meeting, Apr 28, 2026, at 09:30 W. Europe Standard Time. New Risk • Feb 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€56.4m market cap, or US$67.1m). New Risk • Dec 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€52.7m market cap, or US$61.9m). Announcement • Oct 24
Magis S.p.A. (BIT:MGS) announces an Equity Buyback for €0.8 million worth of its shares. Magis S.p.A. (BIT:MGS) announces an share repurchase program. Under the program, the company will repurchases up to €0.8 million. The program will valid till 18 months. Major Estimate Revision • Oct 12
Consensus EPS estimates fall by 28% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €79.6m to €76.1m. EPS estimate also fell from €0.766 per share to €0.551 per share. Net income forecast to shrink 42% next year vs 17% decline forecast for Chemicals industry in Italy. Consensus price target down from €14.50 to €12.75. Share price fell 2.8% to €10.30 over the past week. Price Target Changed • Oct 10
Price target decreased by 15% to €12.75 Down from €15.00, the current price target is an average from 2 analysts. New target price is 24% above last closing price of €10.30. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.63 for next year compared to €1.54 last year. New Risk • Oct 01
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2024 fiscal period end). Earnings are forecast to decline by an average of 2.0% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€62.3m market cap, or US$73.0m). New Risk • Sep 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€66.3m market cap, or US$77.6m). Buy Or Sell Opportunity • Sep 24
Now 20% overvalued Over the last 90 days, the stock has fallen 16% to €11.40. The fair value is estimated to be €9.49, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period. Buy Or Sell Opportunity • Sep 01
Now 20% overvalued Over the last 90 days, the stock has fallen 15% to €11.50. The fair value is estimated to be €9.56, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period. Buy Or Sell Opportunity • Aug 13
Now 20% overvalued Over the last 90 days, the stock has fallen 13% to €11.50. The fair value is estimated to be €9.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.5% per annum. Earnings are forecast to decline by 2.5% per annum over the same time period. Major Estimate Revision • Aug 05
Consensus EPS estimates fall by 39% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €86.0m to €81.2m. EPS estimate also fell from €1.59 per share to €0.967 per share. Net income forecast to shrink 37% next year vs 6.0% decline forecast for Chemicals industry in Italy. Consensus price target down from €18.25 to €15.00. Share price fell 16% to €11.60 over the past week. New Risk • Aug 04
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€65.7m market cap, or US$76.1m). Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €11.80, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 15x in the Chemicals industry in Italy. Negligible returns to shareholders over past year. New Risk • Jun 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€78.7m market cap, or US$91.3m). New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€66.1m market cap, or US$75.3m). New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€69.1m market cap, or US$78.4m). Announcement • Apr 15
Magis S.p.A., Annual General Meeting, Apr 28, 2025 Magis S.p.A., Annual General Meeting, Apr 28, 2025, at 16:30 W. Europe Standard Time. Buy Or Sell Opportunity • Apr 04
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 9.9% to €13.30. The fair value is estimated to be €10.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Announcement • Apr 02
Magis S.p.A. announces Annual dividend, payable on May 07, 2025 Magis S.p.A. announced Annual dividend of EUR 0.9200 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025. Buy Or Sell Opportunity • Mar 13
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 2.4% to €13.00. The fair value is estimated to be €10.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Reported Earnings • Sep 29
First half 2024 earnings released First half 2024 results: Revenue: €43.8m (up 4.7% from 1H 2023). Net income: €4.52m (up 1.4% from 1H 2023). Profit margin: 10% (in line with 1H 2023). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Chemicals industry in Italy. New Risk • Sep 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (8.9% increase in shares outstanding). Market cap is less than US$100m (€63.5m market cap, or US$70.9m). New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€51.5m market cap, or US$54.8m). Reported Earnings • Sep 25
First half 2023 earnings released First half 2023 results: Net income: €4.46m (up €4.46m from 1H 2022).